Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.
The effects of EHDP (20 mg/kd/day) and APD (4.5 mg/kg/day) given for three months to patients with severe symptomatic Paget's disease have been compared in an open trial of 17 patients. Both drugs were equally effective in producing a prompt reduction in pair scores, urine hydroxyproline, and serum alkaline phosphatase levels. The remission was maintained for a variable period after stopping treatment. Both drugs were well tolerated, and a one-month course of either drug was not effective. Comparison with published responses from previous studies indicates that EHDP given at this dose as a relatively short course is more effective than a lower dose for a longer period of time; the present study does not suggest that APD has significant advantages.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism; D000077268:Pamidronate
D004164:Diphosphonates; D003404:Creatinine; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D000077268:Pamidronate; D006909:Hydroxyproline